Holding(s) in Company

Jul 30, 2021

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsHolding in CompanyHolding(s) in Company

RNS Number : 1291H
Advanced Medical Solutions Grp PLC
30 July 2021
 

TR-1: Standard form for notification of major holdings


NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached.

Advanced Medical Solutions Group PLC

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)

Non-UK issuer



2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights


X

An acquisition or disposal of financial instruments



An event changing the breakdown of voting rights



Other (please specify):



3. Details of person subject to the notification obligation

Name

Aegon Asset Management UK PLC

City and country of registered office (if applicable)


4. Full name of shareholder(s) (if different from 3.)

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reached :

28/07/2021

6. Date on which issuer notified (DD/MM/YYYY):

30/07/2021

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 8.B 2)

Total of both in % (8.A 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

2.91%

0.00%

2.91%

215,736,709

Position of previous notification (if

applicable)

3.05%

0.00%

3.05%





 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Number of voting rights

% of voting rights

Class/type of

shares
ISIN code (if possible)

Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0004536594

3,292,182

2,975,488

1.53%

1.38%






SUBTOTAL 8. A


6,267,670

2.91%


B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Number of voting rights that may be acquired if the instrument is
exercised/converted.

% of voting rights








SUBTOTAL 8. B 1




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Physical or cash
settlement

Number of voting rights

% of voting rights










SUBTOTAL 8.B.2






 

9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

X

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)


Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in-struments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aegon Asset Management:-
Aegon Asset Management UK PLC

Aegon Asset Management UK ICVC
Aegon Asset Management UK VCIC






10. In case of proxy voting, please identify:

Name of the proxy holder

Aegon Asset Management UK PLC

The number and % of voting rights held


The date until which the voting rights will be held



11. Additional information

Aegon Asset Management UK plc acquires holdings as agent and discretionary manager for underlying clients including: UCITS funds, other collective investment schemes and segregated, institutional clients. Exercise of voting rights is controlled by Aegon Asset Management UK plc.




Place of completion

Edinburgh, Scotland, United Kingdom

Date of completion

29 July 2021


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

HOLURVSRARUBOAR

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.